TY - JOUR
T1 - Clinical necessity of multi-image based (4DMIB) optimization for targets affected by respiratory motion and treated with scanned particle therapy – A comprehensive review
AU - Knopf, Antje Christin
AU - Czerska, Katarzyna
AU - Fracchiolla, Francesco
AU - Graeff, Christian
AU - Molinelli, Silvia
AU - Rinaldi, Ilaria
AU - Rucincki, Antoni
AU - Sterpin, Edmond
AU - Stützer, Kristin
AU - Trnkova, Petra
AU - Zhang, Ye
AU - Chang, Joe Y.
AU - Giap, Huan
AU - Liu, Wei
AU - Schild, Steven E.
AU - Simone, Charles B.
AU - Lomax, Antony J.
AU - Meijers, Arturs
N1 - Funding Information:
We would like to thank Prof. Dr. med. Damien C. Weber for his thorough review of the final manuscript. Furthermore, we would like to acknowledge that Katarzyna Czerska is partly supported by the EU Project POWR.03.02.00-00- I004/16. Finally, we would like to thank EPTN WP5 4D task group and PTCOG thoracic subcommittee for the endorsement and assistance with preparing this manuscript.
Publisher Copyright:
© 2022 The Author(s)
PY - 2022/4
Y1 - 2022/4
N2 - 4D multi-image-based (4DMIB) optimization is a form of robust optimization where different uncertainty scenarios, due to anatomy variations, are considered via multiple image sets (e.g., 4DCT). In this review, we focused on providing an overview of different 4DMIB optimization implementations, introduced various frameworks to evaluate the robustness of scanned particle therapy affected by breathing motion and summarized the existing evidence on the necessity of using 4DMIB optimization clinically. Expected potential benefits of 4DMIB optimization include more robust and/or interplay-effect-resistant doses for the target volume and organs-at-risk for indications affected by anatomical variations (e.g., breathing, peristalsis, etc.). Although considerable literature is available on the research and technical aspects of 4DMIB, clinical studies are rare and often contain methodological limitations, such as, limited patient number, motion amplitude, motion and delivery time structure considerations, number of repeat CTs, etc. Therefore, the data are not conclusive. In addition, multiple studies have found that robust 3D optimized plans result in dose distributions within the set clinical tolerances and, therefore, are suitable for a treatment of moving targets with scanned particle therapy. We, therefore, consider the clinical necessity of 4DMIB optimization, when treating moving targets with scanned particle therapy, as still to be demonstrated.
AB - 4D multi-image-based (4DMIB) optimization is a form of robust optimization where different uncertainty scenarios, due to anatomy variations, are considered via multiple image sets (e.g., 4DCT). In this review, we focused on providing an overview of different 4DMIB optimization implementations, introduced various frameworks to evaluate the robustness of scanned particle therapy affected by breathing motion and summarized the existing evidence on the necessity of using 4DMIB optimization clinically. Expected potential benefits of 4DMIB optimization include more robust and/or interplay-effect-resistant doses for the target volume and organs-at-risk for indications affected by anatomical variations (e.g., breathing, peristalsis, etc.). Although considerable literature is available on the research and technical aspects of 4DMIB, clinical studies are rare and often contain methodological limitations, such as, limited patient number, motion amplitude, motion and delivery time structure considerations, number of repeat CTs, etc. Therefore, the data are not conclusive. In addition, multiple studies have found that robust 3D optimized plans result in dose distributions within the set clinical tolerances and, therefore, are suitable for a treatment of moving targets with scanned particle therapy. We, therefore, consider the clinical necessity of 4DMIB optimization, when treating moving targets with scanned particle therapy, as still to be demonstrated.
KW - 4D optimization
KW - Motion management
KW - Multi-image-based optimization
KW - Proton therapy
UR - http://www.scopus.com/inward/record.url?scp=85125520743&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125520743&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2022.02.018
DO - 10.1016/j.radonc.2022.02.018
M3 - Review article
C2 - 35189152
AN - SCOPUS:85125520743
SN - 0167-8140
VL - 169
SP - 77
EP - 85
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
ER -